PETX
Aratana Therapeutics Inc.

2,365
Loading...
Loading...
Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.
Sector:
Health Technology
Industry:
Pharmaceuticals Generic
Employees:
83

Frequently Asked Questions

What is Market Cap of Aratana Therapeutics Inc?
What is the 52-week high for Aratana Therapeutics Inc?
What is the 52-week low for Aratana Therapeutics Inc?
What was Aratana Therapeutics Inc stock price yesterday?
What is the PE ratio of Aratana Therapeutics Inc?
What is the Price-to-Book ratio of Aratana Therapeutics Inc?
What is Aratana Therapeutics Inc's EBITDA?
What is the 50-day moving average of Aratana Therapeutics Inc?
How many employess does Aratana Therapeutics Inc has?

Latest PETX News

View
No PETX news at the moment.

Advertisement. Remove ads.

Advertisement. Remove ads.